Chronic
inflammatory demyelinating polyneuropathy or CIDP is a neurological disorder in
which the body immune system attacks myelin which is a vital part of the
nervous system. It occurs when the body immune system cannot distinguish
between the body’s own cell and foreign cell and instead start destroying the
healthy cells of the body. It is also known as chronic relapsing
polyneuropathy. This can cause impaired ability, pain, loss of sensation,
chronic fatigue and other problems, Different treatments can be used to treat
the disease for instance intravenous immunoglobulin, physiotherapy,
plasmapheresis, and others.
Some
of the symptoms are both proximal and distal, orthostatic dizziness, initial
limb weakness, tingling and numbness of hands & feet.
Based
on treatment, Chronic Inflammatory Demyelinating Polyneuropathy market is
segmented into intravenous immunoglobulin (IVIG), plasmapheresis (plasma
exchange), corticosteroids, physiotherapy and others. IVIG segment dominates
the market owing to its preference as the first line of treatment against CIDP.
Based on diagnosis, market is segmented into electro-diagnostic testing, EMG,
nerve conduction, spinal fluid analysis and others. Based on route of
administration, market is segmented into oral, intravenous and others. Based on
distribution channel, market is segmented into retail pharmacy, hospital
pharmacy and online pharmacy. In addition, based on end-user, market is
segmented into hospitals, research & academic laboratories, specialty
neurological clinics and others.
The
Chronic Inflammatory Demyelinating Polyneuropathy market is driven by rise in
research & development (R&D) related to plasma-derived medicines,
followed by growth in prevalence of autoimmune diseases, rise in government
support via awareness programs & drug approvals and increase in awareness
about Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). However, high
cost of the IVIG treatment and side-effects associated with the IVIG treatment
such as hypotension, lower back pain, flushing, nausea, chills, wheezing, etc.
may impact the market. Moreover, growth in advancements in the treatment is a
key opportunity for market.
Based
on geography, the North-American region holds major share, followed by European
region in Chronic Inflammatory Demyelinating Polyneuropathy market owing to
growth in healthcare infrastructure and active government support in the
region. The Asian-Pacific region is anticipated to witness lucrative growth
rate due to rise in emphasis by healthcare organizations & government over
the forecast period. It is projected that the market will be reached at rapid
pace on account of high population & growth in per capita healthcare
spending and increase the prevalence rate of CIDP during the forecast period. The
market is developing at a CAGR of 6.2% and is estimated to reach US $3907.17
million by the end of the forecast period 2018-2023.
To know more, click on
the link below:-
Related Reports:-
Contact Us:-
Ken
Research
Ankur
Gupta, Head Marketing & Communications
+91-9015378249